U.S. markets closed
  • S&P Futures

    3,633.00
    +5.75 (+0.16%)
     
  • Dow Futures

    29,870.00
    +42.00 (+0.14%)
     
  • Nasdaq Futures

    12,181.75
    +29.50 (+0.24%)
     
  • Russell 2000 Futures

    1,850.60
    +6.00 (+0.33%)
     
  • Crude Oil

    45.86
    +0.15 (+0.33%)
     
  • Gold

    1,809.10
    +3.60 (+0.20%)
     
  • Silver

    23.43
    +0.07 (+0.29%)
     
  • EUR/USD

    1.1927
    +0.0009 (+0.07%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3392
    +0.0010 (+0.07%)
     
  • USD/JPY

    104.3230
    -0.1170 (-0.11%)
     
  • BTC-USD

    18,775.88
    -67.25 (-0.36%)
     
  • CMC Crypto 200

    369.21
    -1.31 (-0.35%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,369.98
    +73.12 (+0.28%)
     

Organogenesis Holdings: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Organogenesis Holdings (NASDAQ:ORGO) fell 3.61% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 258.33% over the past year to $0.19, which beat the estimate of ($0.08).

Revenue of $100,799,000 rose by 56.85% from the same period last year, which beat the estimate of $71,960,000.

Guidance

Organogenesis Holdings hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $311,000,000 and $314,000,000.

Conference Call Details

Date: Nov 09, 2020

View more earnings on ORGO

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/xxf78hig

Price Action

52-week high: $8.34

52-week low: $2.47

Price action over last quarter: down 1.23%

Company Profile

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.